9OF0 Stock Chart & Stats
€0.19
-€0.01(-5.56%)
At close: 4:00 PM EDT
€0.19
-€0.01(-5.56%)
Day’s Range― - ―
52-Week Range€0.12 - €1.42
Previous CloseN/A
VolumeN/A
Average Volume (3M)333.00
Market Cap
€3.24M
Enterprise Value€1.27
Total Cash (Recent Filing)€3.59M
Total Debt (Recent Filing)€34.52K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.20
Shares Outstanding1,381,128
10 Day Avg. Volume0
30 Day Avg. Volume333
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.67
Revenue Forecast (FY)€2.15M
Bulls Say, Bears Say
Bulls Say
Cell-therapy PipelineAn adult-stem-cell pipeline aimed at chronic lumbar disc disease and metabolic disorders gives BRTX multiple clinical development paths. If trials and approvals progress, these programs could support licensing, partnering, or future product revenue beyond the company’s current limited commercial base.
Gross Margin PotentialThe reported TTM gross margin of about 63% indicates that existing revenue carries meaningful direct-margin potential. While operating costs currently overwhelm gross profit, preserving this margin could improve incremental economics if commercialization expands and fixed R&D spending is leveraged.
Low LeverageDebt-to-equity at 0.0 in 2024 through TTM periods limits interest burden and creditor pressure relative to a similarly loss-making biotech. Low leverage provides some balance-sheet flexibility for research and development, although declining equity shows financing capacity is not unlimited.
Bears Say
Persistent Cash BurnHeavy and persistent operating and free-cash-flow deficits show that BRTX cannot currently fund its activities from internally generated cash. Continued reliance on external financing may constrain clinical execution, increase dilution or borrowing needs, and weaken strategic flexibility.
Weak Revenue And ProfitabilityVery small and sharply declining revenue is far below the company’s operating cost base, producing deeply negative profitability and large EBIT and EBITDA losses. This gap indicates that BRTX remains substantially dependent on successful development and future commercialization to establish a sustainable business.
Executive And Governance InstabilityAn immediate senior R&D resignation combined with disputed employment terms and a board investigation creates continuing governance and execution risk. Management disruption can slow clinical and corporate decisions, while potential severance obligations may further pressure scarce financial resources.
BioRestorative Therapies News
9OF0 FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was €0.12 and its highest was €1.42 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is €3.24M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is Nov 18, 2026 which is in 58 days.
How were BioRestorative Therapies’s earnings last quarter?
Currently, no data Available
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Overvalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 1,381,128 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in DE:9OF0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioRestorative Therapies
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.